With data to propel it into PhIII, 89bio asks market for nearly $100M to bankroll ex-Teva drug

89bio, born out of a Teva drug, is the latest to board the speed rail that takes biotechs from positive clinical data drop to cash request within a minute.

The San Francisco biotech revealed a mid-stage test that passed muster in a high-fat condition that sometimes leads to cardiovascular...

Click to view original post